【Abstract】 Recently, several studies have been carried about maintenance therapy in non-small cell lung cancer, and some chemotherapy agents have been approved for clinical practice. But there are still a lot of questions about maintenance therapy that we have to consider. For example, the defects of design in maintenance therapy trials; how to choose gold standard of maintenance therapy for evaluation; who bene t from the maintenance therapy and how to estimate pharmaceutical economics. In this paper, we will make deep analysis about these issues.
www.lungca.org Belani [7] Gemcitabine N/A* 17
IFCT-GFPC 0502 [8] Gemcitabine Erlotonib N/A* 91 PARAMOUNT [9, 10] Pemetrexed N/A* 64
Gefitinib 30 (includes Erlotonib) 67 *N/A not applicable, study of continuation maintenance, all patients received drug as part of induction.
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